ECSP088519A - Metodos para preparar rapamicina cristalina y para medir la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido - Google Patents

Metodos para preparar rapamicina cristalina y para medir la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido

Info

Publication number
ECSP088519A
ECSP088519A EC2008008519A ECSP088519A ECSP088519A EC SP088519 A ECSP088519 A EC SP088519A EC 2008008519 A EC2008008519 A EC 2008008519A EC SP088519 A ECSP088519 A EC SP088519A EC SP088519 A ECSP088519 A EC SP088519A
Authority
EC
Ecuador
Prior art keywords
rapamycin
methods
crystalinity
calorimetry
measure
Prior art date
Application number
EC2008008519A
Other languages
English (en)
Inventor
Subodh S Deshmukh
Mahmoud Mirmehrabi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088519A publication Critical patent/ECSP088519A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Combustion & Propulsion (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analyzing Materials Using Thermal Means (AREA)

Abstract

Se describen los métodos para purificar la rapamicina; también se proveen los métodos para medir la calidad de partícula, el tamaño de partícula medio y la cristalinidad de las muestras que contienen rapamicina o un derivado de la misma.
EC2008008519A 2005-12-07 2008-06-09 Metodos para preparar rapamicina cristalina y para medir la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido ECSP088519A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74800505P 2005-12-07 2005-12-07

Publications (1)

Publication Number Publication Date
ECSP088519A true ECSP088519A (es) 2008-07-30

Family

ID=38117222

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008519A ECSP088519A (es) 2005-12-07 2008-06-09 Metodos para preparar rapamicina cristalina y para medir la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido

Country Status (17)

Country Link
US (1) US20070128731A1 (es)
EP (1) EP1957964A2 (es)
JP (1) JP2009518648A (es)
KR (1) KR20080077147A (es)
CN (1) CN101351702A (es)
AR (1) AR058283A1 (es)
AU (1) AU2006322030A1 (es)
BR (1) BRPI0619592A2 (es)
CA (1) CA2630786A1 (es)
CR (1) CR9985A (es)
EC (1) ECSP088519A (es)
IL (1) IL191545A0 (es)
NO (1) NO20082382L (es)
PE (1) PE20071000A1 (es)
RU (1) RU2008120712A (es)
TW (1) TW200736603A (es)
WO (1) WO2007067566A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380006A4 (en) * 2009-01-21 2012-05-16 Biocon Ltd PROCESS FOR DETERMINING THE SIROLIMUS STABILITY AND METHOD FOR PRODUCING ITS STABLE FORM
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
WO2013022418A1 (en) * 2011-08-05 2013-02-14 Crucible Intellectual Property Llc Nondestructive method to determine crystallinity in amorphous alloy
US20150139270A1 (en) * 2012-04-23 2015-05-21 Apple Inc. Non-destructive determination of volumetric crystallinity of bulk amorphous alloy
ES2897473T3 (es) * 2013-03-15 2022-03-01 Biosensors Int Group Ltd Purificación de derivados de la rapamicina
US9439892B2 (en) 2013-05-16 2016-09-13 Surmodics, Inc. Macrolide particulates, methods for preparation, and medical devices associated therewith
CA2915704C (en) * 2013-06-12 2022-06-21 Surmodics, Inc. Solvent methods for preparing crystalline macrolide particulates, compositions, and articles containing particulates
DE102013110294B4 (de) * 2013-09-18 2016-07-07 Innora Gmbh Limus-Depot-Formulierung auf Ballonkathetern
WO2015181826A1 (en) 2014-05-27 2015-12-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Crystalline coating and release of bioactive agents
CN105116013A (zh) * 2015-04-23 2015-12-02 山东农业大学 一种确定金属离子对蛋白酶水解大豆分离蛋白影响的方法
JP6531488B2 (ja) * 2015-05-22 2019-06-19 日産自動車株式会社 リチウムイオン二次電池の熱履歴検知方法
EP3435988B1 (en) 2016-03-31 2021-10-06 Surmodics, Inc. Drug-containing particulate composition with cationic agent, associated medical devices, and methods for treatment
US11123459B2 (en) 2016-12-16 2021-09-21 Surmodics, Inc. Hydrophobic active agent particle coatings and methods for treatment
US11629222B2 (en) * 2019-07-01 2023-04-18 Ethicon, Inc. Calorimetric crystallization method for evaluation of monomer purity
WO2023158308A1 (en) 2022-02-18 2023-08-24 Technische Universiteit Delft Novel method for analyzing dsc data
NL2031004B1 (en) * 2022-02-18 2023-09-05 Univ Delft Tech Novel method for analyzing DSC data
CN116794248B (zh) * 2023-04-20 2026-01-06 广东省药品检验所（广东省药品质量研究所、广东省口岸药品检验所） 一种防止压片过程中堵塞机器的共处理晶体辅料评价方法
CN118706889A (zh) * 2024-05-31 2024-09-27 瀚晖制药有限公司 一种阿帕他胺固体制剂结晶度的检测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5358909A (en) * 1991-02-27 1994-10-25 Nippon Steel Corporation Method of manufacturing field-emitter
US5358908A (en) * 1992-02-14 1994-10-25 Micron Technology, Inc. Method of creating sharp points and other features on the surface of a semiconductor substrate
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0884585A3 (de) * 1997-06-06 1999-12-29 Netzsch Gerätebau GmbH Vorrichtung zur Differential-Scanning-Kalorimetrie
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
EP1319008B1 (en) * 2000-09-19 2008-10-15 Wyeth Water soluble rapamycin esters
JP2005506174A (ja) * 2001-10-17 2005-03-03 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 粒子形成のための回転子固定子装置および方法
US20060169199A1 (en) * 2003-03-31 2006-08-03 Vilmos Keri Crystallization and purification of macrolides
TW200523266A (en) * 2003-07-24 2005-07-16 Biogal Gyogyszergyar Method of purifying macrolides
KR20060057605A (ko) * 2003-08-07 2006-05-26 와이어쓰 Ｃｃｉ-779의 위치선택적 합성 방법
RU2345999C2 (ru) * 2003-09-03 2009-02-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
AU2005238432A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
JP4224115B2 (ja) * 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成
MX2007001676A (es) * 2004-08-10 2007-04-12 Wyeth Corp Derivados de 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionico y metodos para hacer los mismos.
CA2590254A1 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
AU2005319454B2 (en) * 2004-12-20 2012-08-09 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
CA2595766A1 (en) * 2005-02-09 2006-08-17 Wyeth Cci-779 polymorph and use thereof
CA2599580A1 (en) * 2005-03-02 2006-09-08 Wyeth Recovery of cci-779 from mother liquors
US7241771B2 (en) * 2005-03-07 2007-07-10 Wyeth Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin

Also Published As

Publication number Publication date
BRPI0619592A2 (pt) 2016-09-06
CN101351702A (zh) 2009-01-21
EP1957964A2 (en) 2008-08-20
CA2630786A1 (en) 2007-06-14
CR9985A (es) 2008-08-21
AU2006322030A1 (en) 2007-06-14
NO20082382L (no) 2008-09-04
JP2009518648A (ja) 2009-05-07
US20070128731A1 (en) 2007-06-07
WO2007067566A3 (en) 2008-01-24
WO2007067566A2 (en) 2007-06-14
KR20080077147A (ko) 2008-08-21
TW200736603A (en) 2007-10-01
RU2008120712A (ru) 2010-01-20
IL191545A0 (en) 2008-12-29
PE20071000A1 (es) 2007-10-10
AR058283A1 (es) 2008-01-30

Similar Documents

Publication Publication Date Title
ECSP088519A (es) Metodos para preparar rapamicina cristalina y para medir la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
DOP2011000171A (es) Compuestos organico
CR11861A (es) Compuestos organicos
NO20080784L (no) Histondeacetylaseinhibitorer
DOP2011000176A (es) Compuestos organicos
ECSP10010334A (es) Derivados de quinolina y su uso como fungicidas
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
ECSP077271A (es) Derivados de pirimidina
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
DE602006015297D1 (de) 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva
TN2010000061A1 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
UA106880C2 (uk) Нові гербіциди
MY152030A (en) Novel herbicides
NO20080468L (no) Diazepinokinoliner, synteser av disse samt intermediater
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
DE60331310D1 (de) Verfahren zum apoptosenachweis
UY30801A1 (es) Compuestos calciliticos
ECSP088251A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
ATE445593T1 (de) Acetylenderivate
EA200801414A1 (ru) Кальцилитические соединения
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA200801533A1 (ru) Производные антрахинона в качестве маркирующих веществ для жидкостей